Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Phase 3

Completed

• Conditions: Hypertension
• Interventions: Drug: lorundrostat Dose 1; Drug: Placebo; Drug: lorundrostat Dose 2

• Registration Number: NCT06153693
• Lead Sponsor: Mineralys Therapeutics Inc.

Brief Summary

This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications.

Detailed Description

This study is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications, one of which must be a thiazide or thiazide-like diuretic.

The study consists of a 2-week screening period with a 2-week single-blind run-in period followed by a 12-week randomized, double-blind, placebo-controlled, parallel arm period. Following the randomized period subjects will be offered an opportunity to participate in an open-label extension (OLE) study. Any subject electing to not participate in the OLE will undergo an end of study (EoS) visit, which will occur after end of treatment (EoT), to complete their participation in the study.

Study Timeline

• Study First Submitted: 2023-11-17
• Study Start: 2023-11-22
• Study First Submitted QC: 2023-11-22
• Study First Posted: 2023-12-01
• Primary Completion: 2024-12-10
• Study Completion: 2025-01-24
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-21
• Last Update Posted: 2025-02-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1083

Inclusion Criteria

1. At least 18 years of age at the time of signing the informed consent form (ICF)
2. At Screening and Randomization: AOBP SBP of ≥135 and ≤180 mmHg plus AOBP DBP of ≥65 and ≤110 mmHg, or AOBP DBP of ≥90 and ≤110 mmHg
3. Taking between 2 and 5 AHT medications,
4. History of hypertension lasting at least 6 months prior to Screening
5. Body mass index (BMI) of ≥18 kg/m2 at Screening

Exclusion Criteria

1. Women who are pregnant, plan to become pregnant, or are breastfeeding
2. Participation in a study involving any investigational device or small-molecule drug within 4 weeks or 6 months for biologic (antibody) drugs prior to the Screening Visit
3. eGFR <45 mL/min/1.73m2 at Screening, calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula
4. Serum potassium >5.0 mmol/L at Screening or >4.8 mmol/L at Randomization
5. Serum sodium <135 mmol/L (corrected for hyperglycemia) at Screening.
6. History of heart failure, myocardial infarction, stroke, or transient ischemic attack within 6 months prior to the Screening Visit.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Dose 1	lorundrostat Dose 1	50 mg lorundrostat Dose 1 once daily (QD) for 12 weeks
Placebo	Placebo	Placebo once daily (QD) for 12 weeks
Dose 2	lorundrostat Dose 2	50 mg lorundrostat Dose 1 once daily (QD) for 6 weeks then 100 mg lorundrostat Dose 2 once daily (QD) for 6 weeks for subjects who meet prespecified criteria

Primary Outcome Measures

Name	Time	Method
Change from baseline in automated office BP (AOBP) SBP at Week 6 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo	Week 6

Secondary Outcome Measures

Name	Time	Method
Change from baseline in AOBP SBP at Week 12 in subjects randomized to lorundrostat 50 mg QD with escalation to lorundrostat 100 mg QD compared to subjects randomized to placebo	Week 12
Proportion of subjects with AOBP SBP <130 mmHg at Week 6 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo	Week 6
Change from baseline in AOBP SBP at Week 6 in subjects with uncontrolled hypertension on 2 prescribed AHT medications	Week 6	Change from baseline in AOBP SBP at Week 6 in subjects with uncontrolled hypertension on 2 prescribed AHT medications randomized to lorundrostat 50 mg QD compared to subjects with uncontrolled hypertension on 2 prescribed AHT medications randomized to placebo
Change from baseline in AOBP SBP at Week 6 in subjects with uncontrolled hypertension on 3 or more prescribed AHT medications	Week 6	Change from baseline in AOBP SBP at Week 6 in subjects with uncontrolled hypertension on 3 or more prescribed AHT medications (resistant hypertension) randomized to lorundrostat 50 mg QD compared to subjects with uncontrolled hypertension on 3 or more prescribed AHT medications (resistant hypertension) randomized to placebo
Change from baseline in AOBP SBP at Week 6 by obesity status in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo	Week 6
Change from baseline in AOBP SBP at Week 12 in subjects who were escalated to lorundrostat 100 mg QD at week 6 (within-subjects analysis)	Week 12

Trial Locations

Locations (184)

Advanced Cardiovascular, LLC - Alexander City Office; 🇺🇸 Alexander City, Alabama, United States

Central Research Associates, Inc; 🇺🇸 Birmingham, Alabama, United States

Cardiology, P.C.; 🇺🇸 Birmingham, Alabama, United States

Synexus (Radiant Research, Inc) - Alabama - Simon Williamson Clinic Location; 🇺🇸 Birmingham, Alabama, United States

G & L Research LLC - Foley; 🇺🇸 Foley, Alabama, United States

Accel Research Sites (ARS) - Birmingham Clinical Research Unit; 🇺🇸 Vestavia Hills, Alabama, United States

Del Sol Research; 🇺🇸 Tucson, Arizona, United States

Entertainment Medical Group, Inc.; 🇺🇸 Beverly Hills, California, United States

Amicis Research Center - Granada Hills; 🇺🇸 Granada Hills, California, United States

Amicis Research Center - Northridge; 🇺🇸 Granada Hills, California, United States

Scroll for more (174 remaining)